Get the Stockscreener App
0.932
0.25%
-0.0023
After Hours:
.95
0.018
+1.93%
Tscan Therapeutics Inc stock is traded at $0.932, with a volume of 530.68K.
It is down -0.25% in the last 24 hours and down -20.34% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.9343
Open:
$0.95
24h Volume:
530.68K
Relative Volume:
0.82
Market Cap:
$52.89M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.5207
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-9.51%
1M Performance:
-20.34%
6M Performance:
-47.34%
1Y Performance:
-54.31%
1-Day Range:
$0.9267
$0.98
1-Week Range:
$0.9061
$1.025
52-Week Range:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.932 | 53.02M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Is TScan Therapeutics Inc. stock a value trapVolume Spike & Consistent Return Strategy Ideas - mfd.ru
What’s next for TScan Therapeutics Inc. stockQuarterly Market Review & Comprehensive Market Scan Insights - mfd.ru
What are TScan Therapeutics Inc.’s technical support levels2025 Momentum Check & Capital Protection Trade Alerts - mfd.ru
Analysis Recap: Will TScan Therapeutics Inc outperform its industry peersJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug Highlights: How liquid is BlackRock ESG Capital Allocation Term Trust stock2025 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Activity Recap: Will TScan Therapeutics Inc outperform its industry peersMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Investor Mood: How does Waterstone Financial Inc perform in inflationary periodsQuarterly Market Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Financial Contrast: Urogen Pharma (NASDAQ:URGN) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
Take Profit: Is TScan Therapeutics Inc. forming bullish engulfing patternsWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8%What's Next? - MarketBeat
Jobs Data: How much upside does TScan Therapeutics Inc. haveTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Is TScan Therapeutics Inc. stock risky to hold nowMarket Sentiment Report & Daily Entry Point Alerts - bollywoodhelpline.com
Aug Volume: Will TScan Therapeutics Inc stock benefit from M AJuly 2025 Momentum & Verified Stock Trade Ideas - baoquankhu1.vn
Weekly Trades: Will TScan Therapeutics Inc stock benefit from M AMarket Trend Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation - The Globe and Mail
TScan Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView
Aug Momentum: How does TScan Therapeutics Inc score in quality rankingsEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Is TScan Therapeutics Inc. stock a safe haven asset2025 AllTime Highs & Fast Gain Swing Alerts - ulpravda.ru
Is TScan Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & AI Driven Stock Movement Reports - ulpravda.ru
Breakout Move: How institutional buying supports TScan Therapeutics Inc stockJuly 2025 Action & Low Volatility Stock Recommendations - Bộ Nội Vụ
Institution Moves: Is TScan Therapeutics Inc. stock safe for conservative investorsOptions Play & Risk Adjusted Swing Trade Ideas - Улправда
Why TScan Therapeutics Inc. stock attracts global investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Is TScan Therapeutics Inc. stock recession proofPortfolio Risk Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
How institutional buying supports TScan Therapeutics Inc. stock2025 Trading Recap & Stepwise Trade Signal Implementation - Улправда
What risks investors should watch in TScan Therapeutics Inc. stock2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Why TScan Therapeutics Inc. stock is a must watch in 2025Weekly Stock Recap & Consistent Profit Trade Alerts - Улправда
Tech Rally: Why TScan Therapeutics Inc stock appeals to analysts2025 Stock Rankings & Proven Capital Preservation Methods - Bộ Nội Vụ
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Guidance Update: Why TScan Therapeutics Inc stock attracts global investorsMarket Growth Review & Verified Swing Trading Watchlist - Bộ Nội Vụ
Weekly Recap: Will West Fraser Timber Co Ltd stock see PE expansionTrade Volume Report & Growth-Oriented Investment Plans - moha.gov.vn
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat
TScan Therapeutics Earnings Notes - Trefis
How TScan Therapeutics Inc. stock reacts to oil pricesTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
Is TScan Therapeutics Inc. stock safe for conservative investorsJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - DonanımHaber
Will TScan Therapeutics Inc. stock see PE expansionEarnings Miss & Community Consensus Stock Picks - DonanımHaber
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event By Investing.com - Investing.com South Africa
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial - MSN
TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com
Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - setenews.com
TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView
TCRX: TSC-101 shows durable efficacy, safety, and $1.4B+ U.S. market potential in AML/MDS - TradingView — Track All Markets
Investor MeetingKey Opinion Leader - marketscreener.com
TScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire
How Low Can TScan Therapeutics Stock Really Go? - Trefis
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):